 HONG KONG and FLORHAM PARK, N.J., Sept. 29, 2021 GLOBE NEWSWIRE -- HUTCHMED China Limited HUTCHMED NasdaqAIM: HCM; HKEX:13 today announces that, further to its announcement in March 2021 and following receipt of regulatory approval, it has completed the sale of its entire indirect interest in Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited HBYS, a non-core and non-consolidated over-the-counter OTC drug joint venture business, to GL Mountrose Investment Two Limited, a company controlled and managed by GL Capital Group GL Capital. 